Why the Fed Will Not Give Trump's 3% Rate Cut
The White House’s reach on monetary policy is a risk for stock markets. Yet investors continued to ignore both the President’s call for 300 basis point rate cuts and the removal of Fed Chair Powell.Last week, on July 9, Trump wanted the Fed to cut rates by “at least” three percent. That would bring the Fed Funds rate from 4.25%-4.50% down to 1.25%-1.50%. Since the Fed is an independent entity from the White House, stock markets are not pricing in a rate cut of that size. Inflation is still 50-100 basis points above the 2.0% target rate. The job market is still tight, while unemployment rates are low.Since April 3, tariffs have continued to add significant uncertainty to global trade. Large firms may pass most of the tariffs on to customers, while suppliers absorb the remainder. Walmart (WMT) and Costco (COST) are in a trading range in response. Shareholders are willing to pay the 40x P/E on WMT stock and the 55x P/E for COST stock.Small-cap firms cannot easily pass tariffs to customers. This suggests that the Russell 2000 (IWM) is at risk of a correction.U.S. DebtThe U.S. has around $40 trillion in debt. After the “beautiful” tax bill, deficits will rise. That pressures U.S. bond prices, increasing the attractiveness of holding the S&P 500 (SPY) index ETF instead.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


